DiaSorin SpA

DiaSorin S.p.A. researches, develops, manufactures, and distributes immunodiagnostic and molecular diagnostic testing kits in Europe, North America, and other international markets. Its immunodiagnostic offerings cover areas such as infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under the LIAISON XL and LIAISON XS names. The company also offers Simplexa, a congenital CMV direct kit that detects cytomegalovirus DNA in saliva swab and urine specimens, as well as the LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. In addition, it provides the xMAP technology platform, including in vitro diagnostics. DiaSorin was founded in 1968 and is headquartered in Saluggia, Italy.

0GZX.LSE▼

DiaSorin reports lower first-half profit, confirms full-year 2026 outlook

DiaSorin reported lower revenue and net profit for the first half of 2026. Net revenue declined to EUR 602 million from EUR 619 million in the same period last year, while net profit fell to EUR 84 million from EUR 99 million. The company said higher operating expenses and weaker profitability offset growth in the second quarter, when net revenue rose to EUR 315 million from EUR 306 million and net profit was broadly unchanged at EUR 46 million. DiaSorin reaffirmed its full-year 2026 guidance, expecting revenue growth of about 5 percent to 6 percent and an adjusted EBITDA margin of around 32 percent to 33 percent.

0GZX.LSE ▼

RTTNews·49dRead more →